Optimer, Par Pharmaceutical deal

PRX will acquire 16% of Optimer and will co-develop one of Optimer's antibiotics, now named PAR-101. The compound is in Phase IIa trials to treat C. difficile-associated diarrhea (CDAD) and has Fast ...